Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients With Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Lenvatinib (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Eisai Inc
- 12 Feb 2017 Planned primary completion date changed from 1 Nov 2019 to 30 Nov 2019.
- 21 Oct 2016 Status changed from not yet recruiting to recruiting.
- 06 Jun 2016 New trial record